Clinical Trial

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Study acronym: TRANSCEND
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Protocol Amendment History 2 changes
notable Trial sites reduced: 28 -> 24 locations 2026-05-23
notable Trial sites expanded: 25 -> 28 locations 2026-04-16
Trial Details
NCT Number NCT06423430
Lead Sponsor Abbott Medical Devices
Conditions Treatment Resistant Depression
Enrollment 100 participants
Start Date 2024-09-11
Primary Completion 2027-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-29